{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:34:03Z","timestamp":1780767243332,"version":"3.54.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11262-025-02164-0","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:24:29Z","timestamp":1746883469000},"page":"400-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview"],"prefix":"10.1007","volume":"61","author":[{"given":"Nima","family":"Afshar Moghaddam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Yekanipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sama","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Molavi Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Abarghooi Kahaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Kalantar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Gholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"issue":"8","key":"2164_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1099\/jgv.0.001296","volume":"100","author":"D Wright","year":"2019","unstructured":"Wright D et al (2019) Rift Valley fever: biology and epidemiology. J Gen Virol 100(8):1187\u20131199","journal-title":"J Gen Virol"},{"issue":"10","key":"2164_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/pathogens13100856","volume":"13","author":"K Ebisine","year":"2024","unstructured":"Ebisine K et al (2024) A review of nonhuman primate models of rift valley fever virus infection: progress, challenge strains, and future directions. Pathogens 13(10):856","journal-title":"Pathogens"},{"issue":"1","key":"2164_CR3","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/s41467-021-25833-8","volume":"12","author":"WS Tennant","year":"2021","unstructured":"Tennant WS et al (2021) Modelling the persistence and control of Rift Valley fever virus in a spatially heterogeneous landscape. Nat Commun 12(1):5593","journal-title":"Nat Commun"},{"issue":"1","key":"2164_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2478\/jvetres-2021-0009","volume":"65","author":"M Kwa\u015bnik","year":"2021","unstructured":"Kwa\u015bnik M, Ro\u017cek W, Rola J (2021) Rift valley fever\u2014a growing threat to humans and animals. J Vet Res 65(1):7\u201314","journal-title":"J Vet Res"},{"issue":"20","key":"2164_CR5","doi-asserted-by":"publisher","first-page":"e01112","DOI":"10.1128\/jvi.01112-22","volume":"96","author":"MM Schwarz","year":"2022","unstructured":"Schwarz MM et al (2022) Rift Valley fever virus infects the posterior segment of the eye and induces inflammation in a rat model of ocular disease. J Virol 96(20):e01112-e1122","journal-title":"J Virol"},{"issue":"2","key":"2164_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007979","volume":"14","author":"C Tigoi","year":"2020","unstructured":"Tigoi C et al (2020) High risk for human exposure to Rift Valley fever virus in communities living along livestock movement routes: A cross-sectional survey in Kenya. PLoS Negl Trop Dis 14(2):e0007979","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"2164_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cll.2017.01.004","volume":"37","author":"A Hartman","year":"2017","unstructured":"Hartman A (2017) Rift valley fever. Clin Lab Med 37(2):285\u2013301","journal-title":"Clin Lab Med"},{"issue":"8","key":"2164_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-002694","volume":"5","author":"V Petrova","year":"2020","unstructured":"Petrova V et al (2020) Rift valley fever: Diagnostic challenges and investment needs for vaccine development. BMJ Glob Health 5(8):e002694","journal-title":"BMJ Glob Health"},{"key":"2164_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3762\/bjnano.9.98","volume":"9","author":"J Jeevanandam","year":"2018","unstructured":"Jeevanandam J et al (2018) Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol 9:1050\u20131074","journal-title":"Beilstein J Nanotechnol"},{"key":"2164_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jmv.25798","volume":"9","author":"JS Khalili","year":"2020","unstructured":"Khalili JS et al (2020) Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 9:740\u2013746","journal-title":"J Med Virol"},{"issue":"2","key":"2164_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3201\/eid1902.120941","volume":"19","author":"O Dar","year":"2013","unstructured":"Dar O et al (2013) Rift Valley fever and a new paradigm of research and development for zoonotic disease control. Emerg Infect Dis 19(2):189","journal-title":"Emerg Infect Dis"},{"key":"2164_CR12","volume-title":"Pathogenesis and treatment of Rift Valley fever virus","author":"HN Cartwright","year":"2022","unstructured":"Cartwright HN (2022) Pathogenesis and treatment of Rift Valley fever virus. University of Pittsburgh, USA"},{"key":"2164_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fmicb.2012.00254","volume":"3","author":"M Rusu","year":"2012","unstructured":"Rusu M et al (2012) An assembly model of Rift Valley fever virus. Front Microbiol 3:254","journal-title":"Front Microbiol"},{"issue":"26","key":"2164_CR14","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1073\/pnas.1001760107","volume":"107","author":"DD Raymond","year":"2010","unstructured":"Raymond DD et al (2010) Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc Natl Acad Sci USA 107(26):11769\u201311774","journal-title":"Proc Natl Acad Sci USA"},{"key":"2164_CR15","volume-title":"Spatial epidemiology and predictive modelling of Rift valley fever in Garissa county, Kenya","author":"MO Nanyingi","year":"2018","unstructured":"Nanyingi MO (2018) Spatial epidemiology and predictive modelling of Rift valley fever in Garissa county, Kenya. University of Nairobi, Kenya"},{"issue":"3","key":"2164_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","volume":"95","author":"T Ikegami","year":"2012","unstructured":"Ikegami T (2012) Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res 95(3):293\u2013310","journal-title":"Antiviral Res"},{"key":"2164_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/v12121453","author":"GM Cosseddu","year":"2020","unstructured":"Cosseddu GM et al (2020) Genetic diversity of rift valley fever strains circulating in Namibia in 2010 and 2011. Viruses. https:\/\/doi.org\/10.3390\/v12121453","journal-title":"Viruses"},{"key":"2164_CR18","volume-title":"The interactome of Rift Valley fever phlebovirus-towards the identification of new intervention strategies","author":"TJ Mottram","year":"2018","unstructured":"Mottram TJ (2018) The interactome of Rift Valley fever phlebovirus-towards the identification of new intervention strategies. University of Glasgow, UK"},{"issue":"1","key":"2164_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12864-022-08764-6","volume":"23","author":"J Juma","year":"2022","unstructured":"Juma J et al (2022) Genomic surveillance of Rift Valley fever virus: from sequencing to lineage assignment. BMC Genomics 23(1):520","journal-title":"BMC Genomics"},{"issue":"6","key":"2164_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/vetres\/2010033","volume":"41","author":"M Pepin","year":"2010","unstructured":"Pepin M et al (2010) Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41(6):61","journal-title":"Vet Res"},{"key":"2164_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1756-3305-3-35","volume":"3","author":"M Pfeffer","year":"2010","unstructured":"Pfeffer M, Dobler GJP (2010) Emergence of zoonotic arboviruses by animal trade and migration. Parasites Vectors 3:35","journal-title":"Parasites Vectors"},{"issue":"6","key":"2164_CR22","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","volume":"81","author":"BH Bird","year":"2007","unstructured":"Bird BH et al (2007) Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry. J Virol 81(6):2805","journal-title":"J Virol"},{"issue":"7","key":"2164_CR23","volume":"10","author":"L Cavalerie","year":"2015","unstructured":"Cavalerie L et al (2015) A stochastic model to study Rift Valley fever persistence with different seasonal patterns of vector abundance: new insights on the endemicity in the tropical island of Mayotte 10(7):e0130838","journal-title":"A stochastic model to study Rift Valley fever persistence with different seasonal patterns of vector abundance: new insights on the endemicity in the tropical island of Mayotte"},{"issue":"9","key":"2164_CR24","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1371\/journal.pntd.0001229","volume":"5","author":"OA Hassan","year":"2011","unstructured":"Hassan OA et al (2011) The 2007 rift valley fever outbreak in Sudan. PLoS Negl Trop Dis 5(9):e1229","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"2164_CR25","doi-asserted-by":"publisher","first-page":"19506","DOI":"10.2807\/ese.15.10.19506-en","volume":"15","author":"V Chevalier","year":"2010","unstructured":"Chevalier V et al (2010) Rift Valley fever-a threat for Europe? Eurosurveillance 15(10):19506","journal-title":"Eurosurveillance"},{"key":"2164_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","volume":"85","author":"SC Weaver","year":"2010","unstructured":"Weaver SC, Reisen WK (2010) Present and future arboviral threats. Antiviral Res 85:328\u2013345","journal-title":"Antiviral Res"},{"key":"2164_CR27","unstructured":"Otte, M., et al., Transboundary animal diseases: Assessment of socio-economic impacts and institutional responses. 2004: p. 119\u201326."},{"issue":"4","key":"2164_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0188-4409(02)00378-8","volume":"33","author":"DJ Gubler","year":"2002","unstructured":"Gubler DJ (2002) The global emergence\/resurgence of arboviral diseases as public health problems. Arch Med Res 33(4):330\u2013342","journal-title":"Arch Med Res"},{"issue":"3","key":"2164_CR29","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2020.6041","volume":"18","author":"SS Nielsen","year":"2020","unstructured":"Nielsen SS et al (2020) Rift Valley Fever\u2014epidemiological update and risk of introduction into Europe. EFSA J 18(3):e06041","journal-title":"EFSA J"},{"key":"2164_CR30","unstructured":"Organization, W.H., The control of neglected zoonotic diseases: community based interventions for NZDs prevention and control: report of the third conference organized with ICONZ, DFID-RiU, SOS, EU, TDR and FAO with the participation of ILRI and OIE: 23\u201324 November 2010, WHO Heaquarters, Geneva, Switzerland. 2011, World Health Organization."},{"issue":"42","key":"2164_CR31","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","volume":"33","author":"KL Mansfield","year":"2015","unstructured":"Mansfield KL et al (2015) Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe. Vaccine 33(42):5520\u20135531","journal-title":"Vaccine"},{"issue":"8","key":"2164_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2174\/156652405774962263","volume":"5","author":"R Flick","year":"2005","unstructured":"Flick R, Bouloy M (2005) Rift valley fever virus. Curr Mol Med 5(8):827\u2013834","journal-title":"Curr Mol Med"},{"issue":"11","key":"2164_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1289\/ehp.0901389","volume":"118","author":"JN Mills","year":"2010","unstructured":"Mills JN, Gage KL, Khan AS (2010) Potential influence of climate change on vector-borne and zoonotic diseases: a review and proposed research plan. Environ Health Perspect 118(11):1507\u20131514","journal-title":"Environ Health Perspect"},{"issue":"13","key":"2164_CR34","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1128\/JVI.02641-10","volume":"85","author":"H Boshra","year":"2011","unstructured":"Boshra H et al (2011) Rift valley fever: recent insights into pathogenesis and prevention. J Virol 85(13):6098\u20136105","journal-title":"J Virol"},{"issue":"8","key":"2164_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1086\/378747","volume":"37","author":"TA Madani","year":"2003","unstructured":"Madani TA et al (2003) Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37(8):1084\u20131092","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2164_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami T, Makino S (2011) The pathogenesis of Rift Valley fever. Viruses 3(5):493\u2013519","journal-title":"Viruses"},{"key":"2164_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01509","author":"AL Caroline","year":"2016","unstructured":"Caroline AL et al (2016) Inflammatory biomarkers associated with lethal rift valley fever encephalitis in the lewis rat model. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2015.01509","journal-title":"Front Microbiol"},{"issue":"3","key":"2164_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1086\/345671","volume":"36","author":"M Al-Hazmi","year":"2003","unstructured":"Al-Hazmi M et al (2003) Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 36(3):245\u2013252","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2164_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010233","volume":"16","author":"Z Anywaine","year":"2022","unstructured":"Anywaine Z et al (2022) Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis. PLoS Negl Trop Dis 16(3):e0010233","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2164_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12941-020-0346-5","volume":"19","author":"E Javelle","year":"2020","unstructured":"Javelle E et al (2020) The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal. Ann Clin Microbiol Antimicrob 19(1):4","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"2164_CR41","first-page":"371","volume":"82","author":"SS Kahlon","year":"2010","unstructured":"Kahlon SS et al (2010) Case report: Severe rift valley fever may present with a characteristic clinical syndrome 82(3):371","journal-title":"Case report: Severe rift valley fever may present with a characteristic clinical syndrome"},{"issue":"6","key":"2164_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","volume":"16","author":"T Ikegami","year":"2017","unstructured":"Ikegami T (2017) Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines 16(6):601\u2013611","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"2164_CR43","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/ani11072039","volume":"11","author":"EA Clemmons","year":"2021","unstructured":"Clemmons EA, Alfson KJ, Dutton JWJA (2021) Transboundary animal diseases, an overview of 17 diseases with potential for global spread and serious consequences. Animals 11(7):2039","journal-title":"Animals"},{"issue":"3","key":"2164_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1128\/JCM.01412-08","volume":"47","author":"CA Le Roux","year":"2009","unstructured":"Le Roux CA et al (2009) Development and evaluation of a real-time reverse transcription-loop-mediated isothermal amplification assay for rapid detection of Rift Valley fever virus in clinical specimens. J Clin Microbiol 47(3):645\u2013651","journal-title":"J Clin Microbiol"},{"key":"2164_CR45","unstructured":"Health., W.O.f.A., Rift Valley fever (infection with Rift Valley fever virus). 2018, OIE."},{"issue":"7","key":"2164_CR46","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/v14071577","volume":"14","author":"Y Fang","year":"2022","unstructured":"Fang Y et al (2022) Epidemiology of mosquito-borne viruses in Egypt: a systematic review. Viruses 14(7):1577","journal-title":"Viruses"},{"key":"2164_CR47","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s11259-024-10403-2","volume":"48","author":"JE Medina","year":"2024","unstructured":"Medina JE et al (2024) Exploring viral diversity and metagenomics in livestock: insights into disease emergence and spillover risks in cattle. Veter Res Commun 48:2029","journal-title":"Veter Res Commun"},{"issue":"3","key":"2164_CR48","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.20506\/rst.25.3.1722","volume":"25","author":"A Elfadil","year":"2006","unstructured":"Elfadil A, Hasab-Allah K, Dafa-Allah OM (2006) Factors associated with Rift Valley fever in south-west Saudi Arabia. Rev Sci Tech OIE. 25(3):1137\u20131146","journal-title":"Rev Sci Tech OIE."},{"issue":"1","key":"2164_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jviromet.2012.09.016","volume":"187","author":"J Kortekaas","year":"2013","unstructured":"Kortekaas J et al (2013) European ring trial to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus. J Virol Methods 187(1):177\u2013181","journal-title":"J Virol Methods"},{"key":"2164_CR50","unstructured":"Marghani, M.K., The Effects of Autophagy on the Replication of Zika Virus. 2019: New York Medical College."},{"issue":"8","key":"2164_CR51","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.medmal.2019.09.005","volume":"49","author":"P Fill\u00e2tre","year":"2019","unstructured":"Fill\u00e2tre P, Revest M, Tattevin PJM (2019) Crimean-Congo hemorrhagic fever: An update. Med Mal Infect 49(8):574\u2013585","journal-title":"Med Mal Infect"},{"key":"2164_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1128\/jcm.19.2.225-229.1984","volume":"19","author":"B Niklasson","year":"1984","unstructured":"Niklasson B et al (1984) Detection of human IgG and IgM antibodies to Rift Valley fever by enzyme linked immunosorbent assay. J Clin Microbiol 19:225\u2013229","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2164_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12985-018-1071-y","volume":"15","author":"F Yu","year":"2018","unstructured":"Yu F et al (2018) Comparison of enzyme-linked immunosorbent assay systems using rift valley fever virus nucleocapsid protein and inactivated virus as antigens. Virol J 15(1):178","journal-title":"Virol J"},{"issue":"5","key":"2164_CR54","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","volume":"88","author":"TM Timiryasova","year":"2013","unstructured":"Timiryasova TM et al (2013) Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 88(5):962\u2013970","journal-title":"Am J Trop Med Hyg"},{"key":"2164_CR55","unstructured":"Upreti, D., Diagnostics for Rift Valley fever virus. 2018."},{"issue":"1\u20132","key":"2164_CR56","first-page":"61","volume":"57","author":"C Drosten","year":"2003","unstructured":"Drosten C et al (2003) Molecular diagnostics of viral hemorrhagic fevers 57(1\u20132):61\u201387","journal-title":"Molecular diagnostics of viral hemorrhagic fevers"},{"key":"2164_CR57","unstructured":"Mathengtheng, L., Immunogenicity and serological applications of flavivirus ED III proteins and multiplex RT-PCR for detecting novel Southern African viruses. 2015, University of the Free State."},{"issue":"7","key":"2164_CR58","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.7150\/thno.23856","volume":"8","author":"MS Draz","year":"2018","unstructured":"Draz MS, Shafiee H (2018) Applications of gold nanoparticles in virus detection. Theranostics 8(7):1985\u20132017","journal-title":"Theranostics"},{"issue":"7","key":"2164_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131701","volume":"10","author":"G Wong","year":"2015","unstructured":"Wong G et al (2015) A rapid and low-cost PCR thermal cycler for low resource settings. PLoS ONE 10(7):e0131701","journal-title":"PLoS ONE"},{"issue":"1","key":"2164_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12275-015-4656-9","volume":"53","author":"T Notomi","year":"2015","unstructured":"Notomi T et al (2015) Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects. J Microbiol 53(1):1\u20135","journal-title":"J Microbiol"},{"key":"2164_CR61","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.2174\/0929867328666210714154051","volume":"29","author":"H Filik","year":"2022","unstructured":"Filik H, Avan AA (2022) Nanotechnology-based colorimetric approaches for pathogenic virus sensing: a review. Curr Med Chem 29:2691","journal-title":"Curr Med Chem"},{"issue":"3","key":"2164_CR62","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s13346-020-00818-0","volume":"11","author":"M Chakravarty","year":"2021","unstructured":"Chakravarty M, Vora A (2021) Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res 11(3):748\u2013787","journal-title":"Drug Deliv Transl Res"},{"key":"2164_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2021.105848","volume":"216","author":"JL Duarte","year":"2021","unstructured":"Duarte JL et al (2021) Nanotechnology as a tool for detection and treatment of arbovirus infections. Acta Trop 216:105848","journal-title":"Acta Trop"},{"issue":"2","key":"2164_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21887\/ijvsbt.15.2.17","volume":"15","author":"RH Sayed","year":"2019","unstructured":"Sayed RH et al (2019) Development of a lateral flow kit for detection of IgG and IgM antibodies against rift valley fever virus in sheep. Indian J Vet Sci Biotechnol 15(2):63\u201368","journal-title":"Indian J Vet Sci Biotechnol"},{"issue":"1","key":"2164_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.21608\/ejpa.2021.54028.1016","volume":"19","author":"AAA Elqasem","year":"2021","unstructured":"Elqasem AAA, Mohamed AF (2021) Influence of gold nanoparticles on the immune response to rift valley fever vaccine and related hepatophysiological toxicity, histological, and immunohistochemical alterations. Egypt J Pediatr Allergy Immunol 19(1):37\u201349","journal-title":"Egypt J Pediatr Allergy Immunol"},{"issue":"3","key":"2164_CR66","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12010-017-2592-3","volume":"184","author":"MR Zaher","year":"2018","unstructured":"Zaher MR et al (2018) Colorimetric detection of unamplified rift valley fever virus genetic material using unmodified gold nanoparticles. Appl Biochem Biotechnol 184(3):898\u2013908","journal-title":"Appl Biochem Biotechnol"},{"issue":"5","key":"2164_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128215","volume":"10","author":"N Shafagati","year":"2015","unstructured":"Shafagati N et al (2015) The use of Nanotrap particles in the enhanced detection of Rift Valley fever virus nucleoprotein. PLoS ONE 10(5):e0128215","journal-title":"PLoS ONE"},{"issue":"3","key":"2164_CR68","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cell.2017.11.018","volume":"172","author":"X Wu","year":"2018","unstructured":"Wu X et al (2018) Intrinsic immunity shapes viral resistance of stem cells. Cell 172(3):423-438.e25","journal-title":"Cell"},{"issue":"3","key":"2164_CR69","first-page":"105","volume":"68","author":"A Sleem","year":"2020","unstructured":"Sleem A, Saleh F (2020) Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy. Curr Res Transl Med 68(3):105\u2013110","journal-title":"Curr Res Transl Med"},{"key":"2164_CR70","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijid.2016.11.311","volume":"53","author":"S Devignot","year":"2016","unstructured":"Devignot S et al (2016) Mammalian haploid genetic screen to identify host factors essential for Rift Valley fever virus. Int J Infect Dis 53:125","journal-title":"Int J Infect Dis"},{"key":"2164_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111794","author":"PK Kitandwe","year":"2022","unstructured":"Kitandwe PK et al (2022) An overview of rift valley fever vaccine development strategies. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10111794","journal-title":"Vaccines"},{"key":"2164_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jobb.2023.12.003","author":"A-E Laith","year":"2024","unstructured":"Laith A-E et al (2024) Mosquito-borne diseases: assessing risk and strategies to control their spread in the Middle East. J Biosafety Biosecurity. https:\/\/doi.org\/10.1016\/j.jobb.2023.12.003","journal-title":"J Biosafety Biosecurity"},{"key":"2164_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070622","author":"A Kr\u00fcger","year":"2021","unstructured":"Kr\u00fcger A et al (2021) Aptamer applications in emerging viral diseases. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph14070622","journal-title":"Pharmaceuticals"},{"issue":"1","key":"2164_CR74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12575-024-00244-3","volume":"26","author":"K Muzammil","year":"2024","unstructured":"Muzammil K et al (2024) Recent advances in crimean-congo hemorrhagic fever virus detection, treatment, and vaccination: overview of current status and challenges. Biol Proced Online 26(1):20","journal-title":"Biol Proced Online"},{"issue":"1","key":"2164_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-020-0346-5","volume":"19","author":"E Javelle","year":"2020","unstructured":"Javelle E et al (2020) The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal. Ann Clin Microbiol Antimicrob 19(1):1\u201318","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"2164_CR76","doi-asserted-by":"publisher","first-page":"06460","DOI":"10.1371\/journal.pntd.0006460","volume":"12","author":"de St. Maurice A","year":"2018","unstructured":"de St. Maurice A et al (2018) Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations. PLoS Negl Trop Dis 12(5):06460","journal-title":"PLoS Negl Trop Dis"},{"key":"2164_CR77","unstructured":"Anjorin, M., The use of antimicrobial peptides, LL-37 and derivatives, to target rift valley fever virus infection. 2021."},{"key":"2164_CR78","unstructured":"Makola, R.T., Cytoprotective effects of lithium on endothelial integrity and immune profiles induced by rift valley fever virus on huvec and raw 264.7 cells. 2021."},{"key":"2164_CR79","doi-asserted-by":"publisher","first-page":"e52716","DOI":"10.7554\/eLife.52716","volume":"9","author":"PJ Wichgers Schreur","year":"2020","unstructured":"Wichgers Schreur PJ et al (2020) Multimeric single-domain antibody complexes protect against bunyavirus infections. Elife 9:e52716","journal-title":"Elife"},{"issue":"1","key":"2164_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41541-020-0166-9","volume":"5","author":"JR Harmon","year":"2020","unstructured":"Harmon JR et al (2020) Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses. npj Vaccines 5(1):17","journal-title":"npj Vaccines"},{"issue":"2","key":"2164_CR81","first-page":"100","volume":"13","author":"KB Laupland","year":"2002","unstructured":"Laupland KB (2002) Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults. Can J Infect Dis 13(2):100\u2013106","journal-title":"Can J Infect Dis"},{"key":"2164_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105657","volume":"169","author":"O Gholizadeh","year":"2022","unstructured":"Gholizadeh O et al (2022) Recent advances in treatment Crimean-Congo hemorrhagic fever virus: A concise overview. Microb Pathog 169:105657","journal-title":"Microb Pathog"},{"key":"2164_CR83","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.12688\/f1000research.16189.1","volume":"7","author":"DW Hawman","year":"2018","unstructured":"Hawman DW, Feldmann H (2018) Recent advances in understanding Crimean-Congo hemorrhagic fever virus. F1000Res 7:1715","journal-title":"F1000Res"},{"key":"2164_CR84","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02076-16","author":"J Hinkula","year":"2017","unstructured":"Hinkula J et al (2017) Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and\/or virus-like particles induces protection and survival in challenged mice. J Virol. https:\/\/doi.org\/10.1128\/JVI.02076-16","journal-title":"J Virol"},{"issue":"4","key":"2164_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U et al (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmunity Rev 6(4):257\u2013259","journal-title":"Autoimmunity Rev"},{"key":"2164_CR86","volume-title":"Immunological responses to emerging phleboviruses","author":"E Allen","year":"2020","unstructured":"Allen E (2020) Immunological responses to emerging phleboviruses. University of Oxford, Oxford"},{"issue":"3","key":"2164_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008143","volume":"14","author":"B Gutjahr","year":"2020","unstructured":"Gutjahr B et al (2020) Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects. PLoS Negl Trop Dis 14(3):e0008143","journal-title":"PLoS Negl Trop Dis"},{"key":"2164_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00556-21","author":"N Cartwright Haley","year":"2021","unstructured":"Cartwright Haley N, Barbeau Dominique J, McElroy Anita K (2021) Isotype-specific Fc effector functions enhance antibody-mediated rift valley fever virus protection in vivo. mSphere. https:\/\/doi.org\/10.1128\/mSphere.00556-21","journal-title":"mSphere"},{"key":"2164_CR89","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/838491","volume":"2013","author":"G Sautto","year":"2013","unstructured":"Sautto G et al (2013) Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int 2013:838491","journal-title":"Biomed Res Int"},{"key":"2164_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101031","volume":"36","author":"J Zhou","year":"2021","unstructured":"Zhou J et al (2021) Nanotechnology for virus treatment. Nano Today 36:101031","journal-title":"Nano Today"},{"key":"2164_CR91","first-page":"529","volume":"4","author":"MG Soliman","year":"2017","unstructured":"Soliman MG et al (2017) Immune enhancing potential of sphere and rod gold nanoparticles to Rift Valley fever vaccine relative to time: in vitro study. Eur J Biomed Pharm Sci 4:529\u2013536","journal-title":"Eur J Biomed Pharm Sci"},{"issue":"6","key":"2164_CR92","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1039\/C1NR11188D","volume":"4","author":"Y-C Yeh","year":"2012","unstructured":"Yeh Y-C, Creran B, Rotello VM (2012) Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale 4(6):1871\u20131880","journal-title":"Nanoscale"},{"issue":"5","key":"2164_CR93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14760584.2020.1758070","volume":"19","author":"LA Dykman","year":"2020","unstructured":"Dykman LA (2020) Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases. Expert Rev Vaccines 19(5):465\u2013477","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"2164_CR94","first-page":"112","volume":"4","author":"RA El Sayed","year":"2017","unstructured":"El Sayed RA, Mohamed AF (2017) Assessment of neurological toxicity of gold sphere and rod nanoparticles used as adjuvant to rift valley fever virus vaccine (rvfv) and related physiological changes: in vivo study. EJBPS 4(7):112\u2013123","journal-title":"EJBPS"},{"issue":"5","key":"2164_CR95","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.nano.2016.01.021","volume":"12","author":"B Borrego","year":"2016","unstructured":"Borrego B et al (2016) Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. Nanomedicine 12(5):1185\u20131192","journal-title":"Nanomedicine"},{"issue":"10","key":"2164_CR96","first-page":"2673","volume":"166","author":"M Fawzy","year":"2021","unstructured":"Fawzy M et al (2021) Nanoparticles as a novel and promising antiviral platform in veterinary medicine. Adv Virol 166(10):2673\u20132682","journal-title":"Adv Virol"},{"issue":"3","key":"2164_CR97","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13205-020-2076-y","volume":"10","author":"AF El-Sissi","year":"2020","unstructured":"El-Sissi AF et al (2020) Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine. 3 Biotech 10(3):88","journal-title":"3 Biotech"},{"key":"2164_CR98","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1021\/acsabm.1c00426","volume":"4","author":"A Kuskov","year":"2021","unstructured":"Kuskov A et al (2021) Amphiphilic Poly( N -Vinylpyrrolidone) nanoparticles loaded with DNA plasmids encoding Gn and Gc glycoproteins of the rift valley fever virus: preparation and in vivo evaluation. ACS Appl Bio Mater 4:6084","journal-title":"ACS Appl Bio Mater"},{"issue":"5","key":"2164_CR99","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/pharmaceutics14050925","volume":"14","author":"A Kuskov","year":"2022","unstructured":"Kuskov A et al (2022) Amphiphilic Poly-N-vinylpyrrolidone nanoparticles as carriers for nonsteroidal, anti-inflammatory drugs: pharmacokinetic, anti-inflammatory, and ulcerogenic activity study. Pharmaceutics 14(5):925","journal-title":"Pharmaceutics"},{"issue":"8","key":"2164_CR100","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1021\/acsabm.1c00426","volume":"4","author":"A Kuskov","year":"2021","unstructured":"Kuskov A et al (2021) Amphiphilic poly(N-Vinylpyrrolidone) nanoparticles loaded with DNA plasmids encoding Gn and Gc glycoproteins of the rift valley fever virus: preparation and in vivo evaluation. ACS Appl Bio Mater 4(8):6084\u20136092","journal-title":"ACS Appl Bio Mater"},{"key":"2164_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.799942","author":"S Zhang","year":"2022","unstructured":"Zhang S et al (2022) Bacterium-like particles displaying the rift valley fever virus Gn head protein induces efficacious immune responses in immunized mice. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.799942","journal-title":"Front Microbiol"},{"issue":"5","key":"2164_CR102","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1021\/acs.molpharmaceut.0c00054","volume":"17","author":"J Gonzalez-Valdivieso","year":"2020","unstructured":"Gonzalez-Valdivieso J et al (2020) A DNA vaccine delivery platform based on elastin-like recombinamer nanosystems for rift Valley fever virus. Mol Pharm 17(5):1608\u20131620","journal-title":"Mol Pharm"},{"issue":"5","key":"2164_CR103","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1111\/tbed.14415","volume":"69","author":"CL Campbell","year":"2022","unstructured":"Campbell CL et al (2022) Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes. Transbound Emerg Dis 69(5):2621\u20132633","journal-title":"Transbound Emerg Dis"},{"issue":"11","key":"2164_CR104","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S1473-3099(24)00375-X","volume":"24","author":"I Leroux-Roels","year":"2024","unstructured":"Leroux-Roels I et al (2024) Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. Lancet Infect Dis 24(11):1245\u20131253","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2164_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009852","volume":"16","author":"KN Gerken","year":"2022","unstructured":"Gerken KN et al (2022) Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021. PLoS Negl Trop Dis 16(1):e0009852","journal-title":"PLoS Negl Trop Dis"},{"key":"2164_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/v13030367","author":"KE Havranek","year":"2021","unstructured":"Havranek KE et al (2021) The atypical kinase RIOK3 Limits RVFV propagation and is regulated by alternative splicing. Viruses. https:\/\/doi.org\/10.3390\/v13030367","journal-title":"Viruses"}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-025-02164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11262-025-02164-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-025-02164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:09:52Z","timestamp":1779797392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11262-025-02164-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1007\/s11262-025-02164-0","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}